CRBP
Corbus Pharmaceuticals Holdings, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.46
−1.33%Sep 29, 2026, 12:00 UTC
Corbus Pharmaceuticals announced that the first patient has been dosed in its TEMPO-1 registrational study of CRB-701 in second-line and beyond oropharyngeal squamous cell carcinoma.
Source:Sep 14, 2026, 14:49 UTC
Corbus Pharmaceuticals Holdings reported topline results from its CANYON-1 Phase 1b trial evaluating CRB-913 as an obesity treatment, with the drug avoiding depressive effects.
Source:Aug 6, 2026, 00:00 UTC
Corbus Pharmaceuticals Holdings, Inc. reported a net loss of approximately $35.0 million for Q2 2026, with a net loss per share of $1.81.
Jul 28, 2026, 12:00 UTC
The U.S. Food and Drug Administration cleared Corbus Pharmaceuticals to initiate its registrational study TEMPO-1 of CRB-701 in patients with second-line oropharyngeal squamous cell carcinoma.
Jul 6, 2026, 00:00 UTC
Corbus Pharmaceuticals Holdings, Inc. entered into a 2-year employment agreement with Leonardo Viana Nicacio to serve as Chief Medical Officer, effective August 3, 2026.